Breast cancer survivors can lose weight through modest lifestyle changes
the ONA take:
Female breast cancer survivors may be able to lose weight through modest lifestyle changes, according to a recent study presented at the American Society of Clinical Oncology (ASCO) 2015 meeting in Chicago.
Tim Byers, MD, MPH, of the University of Colorado Cancer Center and fellow researchers looked at 700 women at four sites around the U.S. for two years as part of a randomized control trial in which half of the participants underwent lifestyle interventions.
“The goal was to lose seven percent of their body weight and maintain it for two years,” said study collaborator Rebecca Sedjo, PhD. The women in the intervention group attended motivational meetings which focused on increasing physical activity and decreasing caloric intake.
Within the first 12 months, average weight loss among the participants in the intervention group was six percent of total body weight.
“This is a significant finding because it shows that women are able to lose weight after breast cancer treatment and this may lead to reduced risk of recurrence,” said Dr. Byers.
Female breast cancer survivors may be able to lose weight through modest lifestyle changes.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Definitive IMRT Associated With Shorter Feeding Tube Placement Duration in HNC
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|